Publication: Prednisone and deflazacort in Duchenne muscular dystrophy: A patient perspective and plain language summary publication of the Cincinnati study
This article in the Journal of Comparative Effectiveness Research summarizes the Cincinnati study, which investigated the effectiveness of 2 corticosteroid treatments in prolonging motor function in Duchenne muscular dystrophy (DMD)
Explore the outcomes from the Cincinnati study
Learn about the background and demographics of the 435 boys with DMD who took part in the study
Compare patient outcomes to understand the differences between 2 corticosteroid treatments
Wong BL, Cook T, Miller H. J Comp Eff Res. 2022;11(11):779–786
Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older. PTC Therapeutics is the Marketing Authorization Holder for deflazacort in the US only. Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The US Prescribing Information for deflazacort is available here. Please refer to your local country guidance for more information.
For medical information, product complaints, or to report an adverse event, please call 1-866-562-4620 or email at firstname.lastname@example.org. You may also report adverse events directly to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Once registered, you will be able to view the abstract and be provided the DOI and PubMed links for this publication.
Register now to unlock the content
Register now to access the content on this page
If not, register below
MED-ALL-DMD-2300173 | January 2024
Sign in or register to access exclusive content on this site